Exacis Biotherapeutics Announces Its Launch and mRNA Technology In-Licensing for Targeted CAR-NK and CAR-T Cell Cancer Therapies

Exacis Biotherapeutics

  • Focuses on immuno-oncology
  • Creates innovative, engineered T and NK cells from induced pluripotent stem cells (iPSC)
  • In-licenses mRNA technologies developed by Factor Bioscience
  • Uses mRNA-based approach to create cell therapies – avoids viruses and DNA
  • Names key executives including Gregory Fiore, MD, as Chief Executive Officer

Cambridge, MA, January 6, 2021 – Exacis Biotherapeutics, Inc., a development-stage immuno-oncology company working to harness the immune system to cure cancer, today announced its formation along with completion of in-licensing of certain technologies from Factor Bioscience, a leading cell sciences company. The exclusive license allows Exacis to create allogeneic engineered T and NK cells from induced pluripotent stem cells (iPSC). Exacis’ next generation approach avoids use of DNA and viruses by using mRNA. The technologies will be used for generating iPSC and for performing genetic editing to create stealthed, allogeneic cell products, termed ExaCAR-T™ or ExaCAR-NK™ cells.

Exacis also announced the addition of key members to its leadership team, Scientific Advisory Board and Board of Directors. Gregory Fiore, MD, a Harvard trained physician, seasoned pharmaceutical executive and serial entrepreneur, has been named Chief Executive Officer. Dr. Fiore is joined on the management team by co-founder and Head of Discovery and Development, James Pan, PhD, an entrepreneur and biologics expert. Dimitrios Goundis, PhD, formerly CEO of MaxiVAX, a private Swiss immuno-oncology company, joins Exacis as the Chief Business Officer.

Exacis was launched by Factor Bioscience with an exclusive license to its intellectual property for developing targeted, allogeneic cell therapies for cancer treatment. Factor CEO Matthew Angel, PhD, is the Chair of Exacis’ Scientific Advisory Board and is joined on the SAB by Factor Co-Founder Christopher Rohde, PhD, Eric Westin, MD, and Gunnar Kaufmann, PhD. Exacis’ Board of Directors is chaired by Mark Corrigan, MD, a highly successful drug developer, biotechnology CEO and Board Chairperson.

Commenting on the new endeavor, Dr. Fiore said, “This is a wonderful opportunity to create innovative, next-generation NK and T cell therapies to improve outcomes and experiences for patients with challenging liquid and solid tumors.”

Exacis’ Board Chairman Corrigan added, “The ground- breaking science Exacis has in-licensed, along with the team we are building, provide a strong foundation for developing successful targeted cell therapies for the treatment of cancer.”

Exacis has secured initial seed funding and is seeking to raise Series A funding in early 2021. The company has initiated discussions with several potential development collaborators.

About Exacis Biotherapeutics

Exacis is a development stage biotechnology company focused on harnessing the human immune system to cure cancer by engineering off-the-shelf NK and T cell therapies aimed at liquid and solid tumors. Exacis was founded in 2020 with an exclusive license to a broad suite of patents covering the use of technologies developed by Factor Biosciences.

About Factor Bioscience

Founded in 2011, Factor Bioscience develops technologies for engineering cells to advance the study and treatment of disease. It actively licenses its technologies to entities wishing to conduct commercial research, sell tools, reagents and other products, perform commercial services for third parties, and develop human and veterinary therapeutics. Factor Bioscience is privately held and is headquartered in Cambridge, MA.

About T and Natural Killer (NK) Cell Therapies

T and NK cells are types of human immune cells that are able to recognize and destroy cancer cells and can be modified through genetic engineering to target specific tumors.


Contact Exacis Biotherapeutics for further information and media:

Exacis Biotherapeutics

Ted Agne
The Communications Strategy Group Inc.
+1781 888 0099